Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Healthcare Medical Devices
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Profound Medical Corp > Concerns over new ways to fight cancer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by HomerAndCompanyon Nov 08, 2022 7:53am
192 Views
Post# 35081254

RE:Concerns over new ways to fight cancer

RE:Concerns over new ways to fight cancerFrom what I've read the use of mRNA to treat cancer is something that has been in the works for more than a decade. It's one of a number of new prostate cancer and BPH treatments that are or could be in competetion with Profound's TULSA. 

I think that Profound revenues will be above $50 million when they achieve 1% of the US market, or a small fraction of 1% of the worldwide market. Profound does not need a prostate treatment monopoloy to thrive.    

homer111 wrote: Is anyone here worried how researchers are now using some of these mRNA vaccines (similar to the covid vaccines) to treat cancer and whether that may take some momentum away from PRN? 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities